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Abstract
Background: Tumor cell proliferation is a predictor of survival in cutaneous melanoma. The aim of the present study 
was to evaluate the prognostic impact of mitotic count, Ki-67 expression and novel proliferation markers 
phosphohistone H3 (PHH3), minichromosome maintenance protein 4 (MCM4) and mitosin, and to compare the results 
with histopathological variables.
Methods: 202 consecutive cases of nodular cutaneous melanoma were initially included. Mitotic count (mitosis per 
mm2) was assessed on H&E sections, and Ki-67 expression was estimated by immunohistochemistry on standard 
sections. PHH3, MCM4 and mitosin were examined by staining of tissue microarrays (TMA) sections.
Results: Increased mitotic count and elevated Ki-67 expression were strongly associated with increased tumor 
thickness, presence of ulceration and tumor necrosis. Furthermore, high mitotic count and elevated Ki-67 expression 
were also associated with Clark's level of invasion and presence of vascular invasion. High expression of PHH3 and 
MCM4 was correlated with high mitotic count, elevated Ki-67 expression and tumor ulceration, and increased PHH3 
frequencies were associated with tumor thickness and presence of tumor necrosis. Univariate analyses showed a worse 
outcome in cases with elevated Ki-67 expression and high mitotic count, whereas PHH3, MCM4 and mitosin were not 
significant. Tumor cell proliferation by Ki-67 had significant prognostic impact by multivariate analysis.
Conclusions: Ki-67 was a stronger and more robust prognostic indicator than mitotic count in this series of nodular 
melanoma. PHH3, MCM4 and mitosin did not predict patient survival.
Background
Cutaneous melanoma is one of the most rapidly increas-
ing malignancies among Caucasians [1,2], and improved
understanding of its biological characteristics and prog-
nostic factors is therefore important. Advanced stage dis-
ease is relatively resistant to conventional therapeutic
approaches [3], and better insight in the molecular patho-
genesis of melanoma development and progression could
contribute to improved diagnostic tools and new strate-
gies for targeted therapy. Since tumor cell proliferation is
an increasingly important prognostic factor in many
malignant tumors, its value in cutaneous melanoma has
been examined in the present report by a comparison of
several different markers.
The 2002 American Joint Committee on Cancer
(AJCC) staging system for melanoma was based on a
multicenter analysis of prognostic factors in more than
17,000 patients [4]. The pT classification included infor-
mation on tumor ulceration, but not mitotic count [5]. In
some recent studies, however, mitotic frequency is a pow-
erful predictor of survival [6-11], and the inclusion of this
marker in staging of primary melanomas has been
included in the 2010 edition of the AJCC pTNM staging
system.
The proliferation marker Ki-67 is expressed in all
phases of the cell cycle [12], and elevated Ki-67 in tumor
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Page 2 of 15cells was associated with the most aggressive melanomas
in our previous study [13]. A prognostic significance has
also been shown in other studies [9], but results have not
been consistent [12]. Although Ki-67 positivity is a
marker of proliferative cells, it is uncertain how many of
the cells expressing Ki-67 will actually undergo mitosis.
In 1997, the mitosis marker anti phosphohistone H3
was first introduced [14]. Phosphorylation of histone H3
(Ser 10) is shown to be closely associated with mitotic
chromatin condensation in late G2 and M phase of the
cell cycle [14,15], and histone H3 is not phosphorylated
during apoptosis [16]. Subsequently, expression of PHH3
has been investigated in several cancers. Among brain
tumors, PHH3 staining was primarily found to support
grading by facilitating mitotic counting, but it also had a
prognostic value [17,18]. In a series of lymph node nega-
tive breast cancer patients, PHH3 was the strongest prog-
nostic variable [19]. In a small study of melanocytic
lesions, PHH3 was a useful supplement in differentiating
malignant melanoma from benign nevi, although it did
not show any advantage compared to Ki-67 [20]. To the
best of our knowledge, the prognostic value of PHH3
expression in malignant melanoma has not been previ-
ously evaluated.
In a large gene expression profiling study of primary
human cutaneous melanomas, 254 genes with impact on
metastatic dissemination were characterized [21]. In this
study, immunohistochemical validation identified MCM4
and MCM6 as independent predictors of patient survival.
The MCMs are subunits of the minichromosome mainte-
nance protein complex, MCM2-7, involved in DNA repli-
cation and expressed in all phases of the cell cycle: G1, S,
mitosis and G2 [22,23]. In another recent gene expression
study [24], mitosin was among the genes that were up-
regulated in melanoma metastases compared to primary
melanomas. Mitosin, also termed centromere protein F
(CENP-F), is associated with the centromere/kinethocore
complex and is expressed in all active phases of the cell
cycle, with a maximum in G2 and M [25]. Immunohis-
tochemical studies on breast cancer have shown elevated
expression of mitosin to be correlated with poor progno-
sis [26,27].
Cdc6 has previously been reported as a p16 suppressor
[28]. This protein is a regulator of the cell cycle and
thereby cell proliferation by inhibition of Cyclin-Cdk4/6
complex formation [29]. In our series, loss of p16 expres-
sion is previously shown to be associated with increased
Ki-67 expression and poor outcome [13].
On this background, the aim of our present study was
to evaluate the prognostic impact of mitotic count, Ki-67
expression and novel proliferation markers PHH3,
MCM4, mitosin and Cdc6, and to compare the results
with important histopathological variables.
Methods
Patients
The patient material of this series is described in detail
elsewhere [13]. Briefly, 202 consecutive cases of vertical
growth phase melanoma of the nodular type occurring in
the period 1981 to 1997 were initially included (median
age 64.4 years, median thickness 3.6 mm, range from 1.0
mm to 44.0 mm). The presence of a vertical growth phase
and the lack of a radial growth phase, i.e. adjacent in situ
or microinvasive components, were used as inclusion cri-
teria. Cases with minor secondary involvement of the
adjacent epidermis up to three epidermal ridges were
included. There was no known history of familial occur-
rence. In addition, 58 paired metastases (local skin,
regional lymph nodes, distant) were examined. During
this period, the sentinel node procedure was not per-
formed.
Complete information on patient survival and time and
cause of death was available in all 202 cases. Last date of
follow-up was December 31, 1999, and median follow-up
time for survivors was 89 months (range from 24 to 221).
Recurrence-free survival was available in 167 of 202
patients. During the follow-up period, 72 patients (36%)
died of malignant melanoma, and 45 (22%) died of other
causes. Of the 167 radically treated patients with data on
recurrence-free survival, 74 (44%) had recurrent disease.
Previously reported information on clinico-pathologi-
cal characteristics and survival data [13], the proliferation
marker Ki-67 [13], cell cycle regulators [13,30,31] and
EZH2 expression [32] were included for comparison.
In addition to this series of nodular melanoma, 32 cases
of benign melanocytic nevi (median age 26.6 years) and
20 consecutive cases of invasive superficial spreading
melanomas >1 mm in thickness (median age 49.0 years,
median thickness 1.7 mm) occurring in the period 1981
to 1983 were included to examine various markers in dif-
ferent categories of melanocytic lesions.
In this study, mitotic count and Ki-67 expression [13]
were assessed on standard sections of all the 202 cases of
primary malignant melanoma. Tissue microarray (TMA)
sections were used for examination of PHH3, MCM4,
mitosin and Cdc6; 96-129 cases had sufficient material
left in the TMA blocks for these markers. Comparisons
between regular slides and TMA sections were done (see
Results).
TMA sections of benign nevi, superficial spreading
melanomas and metastases were stained for PHH3,
MCM4, mitosin and Cdc6. Mitotic count was not exam-
ined in these cases. Ki-67 expression was examined in
standard sections of the metastases, but not in benign
nevi or superficial spreading melanomas.
The Norwegian Data Inspectorate and the Regional
Committee for Ethics in Research (Health Region III)
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formed in accordance with the Helsinki Declaration.
Clinico-pathological variables
The following variables were recorded: date of histologi-
cal diagnosis, sex, age at diagnosis, anatomical site of the
primary tumor, and presence of metastases at diagnosis
(local, regional, distant). The H&E-stained slides were
previously re-examined, and the following histological
features included: tumor thickness according to Breslow
[33], level of invasion according to Clark [34], micro-
scopic tumor ulceration [35], necrosis [36], and vascular
invasion [35].
Mitotic count
The mitotic count was recorded on H&E stained sections
using light microscope (×400). Mitotic figures were
counted at the base of the tumors in the most active area
("hot spots") in a minimum of 3 consecutive HPFs (HPF
size 0.29 mm2), and the number of mitosis per mm2 was
calculated (IMB, LAA).
Tissue Microarray (TMA)
The TMA technique has been described and validated in
several studies [37-39]. Three tissue cylinders with a
diameter of 0.6 mm [38,39] from representative tumor
areas identified on H&E stained slides, generally at the
suprabasal areas of the primary tumors, were punched
and mounted into a recipient paraffin block using a cus-
tom-made precision instrument (Beecher Instruments,
Silver Spring, MD, USA). Sections of the resulting TMA
blocks (5 μm) were then made by standard technique.
Immunohistochemistry
The immunohistochemical staining was performed on
thin TMA sections (5 μm) of paraffin-embedded archival
tissue. The slides were dewaxed with xylene/ethanol
before microwave antigen retrieval for 10 min at 750 W
and 15 min at 350 W in TE 9 buffer (pH = 9) or citrate
butter (pH = 6). The staining protocols were optimized
for each of the antibodies. The Ki-67 staining protocol
and evaluation are previously described [13].
PHH3
Antigen retrieval was carried out in Tris-EDTA buffer.
The slides were incubated for 1 hour at room tempera-
ture with a polyclonal rabbit Phosphohistone H3 anti-
body (Ser 10), catalogue # 06-570 (Millipore, Billerica,
MA, USA), diluted 1:1500.
MCM4
The microwave treatment was performed in Tris-EDTA
buffer, before incubation for 1 hour at room temperature
with a monoclonal mouse MCM4 antibody, catalogue #
sc-28317 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), diluted 1:25.
Mitosin
After microwave treatment in citrate buffer, the TMA
slides were incubated overnight at 4°C with the poly-
clonal rabbit CENPF antibody, catalogue # ab5 (Abcam,
Cambridge, UK), diluted 1:100.
Cdc6
Microwave antigen retrieval was performed in citrate
buffer, followed by incubation overnight at 4°C with the
monoclonal mouse Cdc6 antibody, catalogue # sc-9964
(Santa Cruz Biotechnology, Santa Cruz, CA, USA),
diluted 1: 20.
The staining procedures were performed using the
EnVision labelled polymer method (Dako, Copenhagen,
Denmark), with 3-amino-9-ethylcarbazole (AEC) peroxi-
dase as substrate before brief counterstaining with Dako
REAL hematoxylin.
Negative controls were incubated with mouse IgG of
the same isotype and in the same dilution in the cases of
monoclonal antibodies, MCM4 and Cdc6. In the PHH3
and mitosin protocols, the negative controls were
obtained by omitting the primary antibody. All turned
out negative.
Evaluation of staining
PHH3
The staining of PHH3 was evaluated by counting of posi-
tive cells in prophase, metaphase, anaphase or telophase
(Fig. 1). In general, the staining of PHH3 was strong and
crisp, with no background. Some interphase nuclei
showed sparse granular staining, but these were not
counted. The percentage of positive tumor cell nuclei was
counted in 5 × 100 cells for each case (magnification
×400, field size 0.18 mm2) in selected areas with most
positive nuclei, i.e. "hot spots". A subset (n = 50) was
scored blindly by two observers (RGL, IMB) showing
good agreement (Spearman's correlation coefficient 0.82,
p < 0.001; κ = 0.72).
The number of positive tumor cell nuclei per HPF was
also estimated in all the cases, as the average of the count
in 3 HPFs at ×400 magnification, and there was a signifi-
cant correlation with percentage positive nuclei (Spear-
man's correlation coefficient 0.93, p < 0.001).
For internal validation, 25 regular slides of primary
melanomas were stained for PHH3, and both the per-
centage of positive tumor cell nuclei and the average
number of positive tumor cell nuclei per HPF correlated
well with the results from the TMA sections (Spearman's
correlation coefficient 0.80 and 0.74, respectively, both p
< 0.001).
MCM4
Staining of MCM4 was mainly nuclear (Fig. 1). Evaluation
was assessed by recording the percentage positive tumor
cell nuclei as described for PHH3. A subset (n = 22) was
examined blindly by two of the authors (RGL, IMB)
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0.70).
Mitosin
The nuclear immunohistochemical staining of mitosin
was generally fairly strong (Fig. 1), and recorded using a
semi-quantitative and subjective grading, considering
both the intensity of staining and the proportion of tumor
cell nuclei showing unequivocal positive reaction. A
staining index (SI) was calculated as a product of staining
intensity (0-3) and area of positive tumor cell; 1 < 10%, 2 =
10-50%, 3 > 50%; [32]. The staining of all primary mela-
nomas was scored blindly by two investigators (κ = 0.57).
In the cases of disagreement, slides were re-evaluated by
both observers (RGL, IMB) to obtain a consensus.
Cdc6
The staining of Cdc6 in tumor cells was primarily cyto-
plasmic and recorded by the same grading system as
mitosin, with the difference that cytoplasmic staining
intensity and area was evaluated instead of the nuclear
staining. There was good correlation regarding the
assessment of the staining index in primary melanomas
(n = 116) by two observers (RGL, IMB) (κ = 0.74).
Evaluation of the cases was done blinded for patient
characteristics and outcome. In subsequent statistical
analyses, the cut-off point for categorization was based
on the median values for PHH3 and MCM4, the lower
quartile SI for mitosin and the median SI for Cdc6, after
considering the frequency distribution curve and size of
subgroups as well as number of events. PHH3 and
MCM4 were categorized as low and high by the median
percentage of positive tumor cell nuclei, 0.8% and 40.7%,
respectively. Mitosin and Cdc6 were categorized as low
and high, with cut-off points at SI = 6 and SI = 4, respec-
tively.
Statistics
Analyses were performed using the SPSS statistical pack-
age, version 15.0 (SPSS Inc, Chicago, IL). Associations
between different categorical variables were assessed by
Pearson's chi-square test. Continuous variables not fol-
Figure 1 Immunohistochemical staining showing PHH3 positive prophases and mitotic figures (A and B), high expression of MCM4 (C) and 
mitosin (D).
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two or more groups using the Mann-Whitney U or
Kruskal-Wallis H tests. Wilcoxon signed rank test was
used to compare related samples. Nonparametric correla-
tions were tested by the Spearman's rank coefficient, and
Kappa (κ) statistics was used in analyses of inter-observer
agreement of categorical data.
Univariate analyses of time to death due to malignant
melanoma or time to recurrence (recurrence-free sur-
vival) were performed using the product-limit procedure
(Kaplan-Meier method), and differences between catego-
ries were estimated by the log-rank test, with date of his-
tological diagnosis as the starting point. Patients who
died of other causes were censored at the date of death.
The influence of co-variates on patient survival and
recurrence-free survival was analysed by the proportional
hazards method, and tested by the likelihood ratio (lratio)
test. All results were considered significant if p ≤ 0.05.
Results
Primary nodular melanoma
Mitotic count
The median value of the mitotic count was 6 mitotic fig-
ures per mm2. Increased mitotic count was strongly asso-
ciated with tumor thickness, presence of ulceration and
tumor necrosis (all p < 0.001; Kruskal-Wallis or Mann-
Whitney test), as well as advanced Clark's level of inva-
sion (p = 0.038) and presence of vascular invasion (p =
0.052) (Table 1). In addition, high mitotic count was asso-
ciated with elevated Ki-67 expression in tumor cells (p <
0.001, R = 0.26 by linear regression, as illustrated in Fig.
2). Among cell cycle regulators, increased mitotic count
was associated with strong EZH2 expression (p = 0.001,
Mann-Whitney test; data not shown).
Ki-67
The median percentage of Ki-67 expression was 27%
(range from 1 to 79%). Elevated Ki-67 expression was cor-
related with increased tumor thickness and presence of
tumor ulceration (both p < 0.001; Kruskal-Wallis or
Mann-Whitney test), tumor necrosis (p = 0.007),
increased Clark's level of invasion (p = 0.015) and vascu-
lar invasion (p = 0.027) (Table 1). Furthermore, the level
of Ki-67 expression was correlated with high EZH2
expression (p = 0.002, Mann-Whitney test; data not
shown).
PHH3
The range of percentage PHH3 positive tumor nuclei was
from 0.0 to 6.6% (median value 0.8%). Increased expres-
sion of PHH3 was significantly associated with tumor
thickness (p = 0.031), presence of tumor ulceration (p =
0.041) and tumor necrosis (p = 0.027), but not with
Clark's level of invasion (Table 1). High levels of PHH3
was associated with increased mitotic count (p = 0.003)
and high Ki-67 expression (p = 0.002) (Table 2). In addi-
tion, elevated PHH3 was associated with high levels of
EZH2 expression (p < 0.001, Mann-Whitney test; data
not shown).
Using regular slides, the recalculated median value of
positive PHH3 nuclei per mm2 was 20.9; the median value
of the mitotic count was 8.6 per mm2 in the same subset
(n = 25) of the primary melanomas. Thus, PHH3 count
was 2.4 times higher than the mitotic count.
MCM4
The proportion of positively stained MCM4 in tumor cell
nuclei was ranging from 0.0 to 84.8% (median value
40.7%). High expression of MCM4 was correlated with
tumor ulceration (p = 0.003), high mitotic count (p =
0.002), but not with other histopathological variables
(Table 1, 2). Elevated MCM4 expression was also associ-
ated with elevated Ki-67 expression (p = 0.001) (Table 2).
Increased MCM4 expression and elevated PHH3 expres-
sion was correlated (Spearman's correlation coefficient
0.55, p < 0.001). Further, high MCM4 expression was cor-
related to high EZH2 expression (p < 0.001, Mann-Whit-
ney test; data not shown).
Mitosin
Mitosin was not correlated with mitotic count, expres-
sion of Ki-67, cell cycle regulators, nor any of the investi-
gated histopathological variables.
Cdc6
Cdc6 was not correlated with mitotic count, Ki-67
expression, MCM4 or mitosin. In the group with high
Cdc6 expression, there was significant higher level of
PHH3 positivity than the group with low Cdc6 expression
(p = 0.042, Mann-Whitney test; data not shown). Notably,
the level of Cdc6 was not correlated with p16 expression
in our series. There was no association between level of
Cdc6 expression and histopathological variables.
Primary and metastatic melanoma
The Ki-67 expression in metastases was significantly
higher than in the corresponding primary melanomas,
with a median value of 43% positivity in metastases com-
pared with 27% in primary nodular melanomas (p =
0.001, Wilcoxon signed ranks test).
There was no significant difference in PHH3 and Cdc6
levels in metastases compared to corresponding primary
tumors, whereas MCM4 and mitosin were significantly
lower in metastases (p < 0.001 and p = 0.012, respectively;
Wilcoxon signed ranks test).
Melanocytic nevi and melanomas
PHH3 expression was higher in melanomas (nodular and
superficial combined, n = 127), when compared with
benign nevi (n = 32) (p < 0.001, Mann-Whitney test). The
median values of percentage positive PHH3 nuclei in the
two groups were 0.8 and 0.0, respectively.
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Table 1: Associations between different proliferation markers and histopathological variables
Mitotic count Ki-67 PHH3 MCM4 Mitosin
(no./mm2) (% pos) (% pos) (% pos) (nc)
median p-valuea median p-valuea median p-valuea median p-valuea low high p-valueb
Tumor thickness <0.001 <0.001 0.031 ns ns
≤2.0 mm 1.7 19.0 0.4 43.0 4 7
2.1-4.0 mm 4.3 26.5 0.8 33.2 17 23
>4.0 mm 9.4 35.0 1.0 44.4 24 28
Tumor ulceration <0.001 <0.001 0.041 0.003 ns
absent 4.3 23.5 0.6 32.0 18 26
present 9.4 33.0 1.4 46.4 27 30
Tumor necrosis <0.001 0.007 0.027 ns ns
absent 4.3 25.0 0.6 37.4 26 38
present 12.0 35.0 1.6 45.2 19 20
Clark's level 0.038 0.015 ns ns ns
II - IV 5.1 26.0 0.8 37.5 35 45
V 7.7 35.0 1.0 47.2 10 13
Vascular invasion 0.052 0.027 ns ns ns
absent 5.1 26.0 0.8 40.6 35 42
present 8.15 34.5 1.0 41.4 10 16
aMann-Whitney or Kruskal-Wallis test
bChi-square test
cStaining index, cut-off point lower quartile
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MCM4 positivity was 36.8% in contrast to 2.0% in nevi (n
= 31) (p < 0.001, Mann-Whitney test).
Mitosin and Cdc6 were also significantly higher in the
group of nodular and superficial melanomas than in nevi
(p < 0.001, Pearson's chi square test).
Survival analyses
Univariate survival analysis showed worse outcome in the
group of patients with high mitotic count (p = 0.008),
using a cut-off at the lower quartile (mitotic count ≥ 1.7
per mm2) (Fig. 3; Table 3). In the subgroup of cases with
high mitotic count, 5-year survival was 62% and 10-year
survival was 51%. In contrast, both 5-year and 10-year
survival were 84% among the rest. Further, univariate sur-
vival analysis showed significant influence of Ki-67
expression (p < 0.0001) (Fig. 3; Table 3). In the cases with
high Ki-67 expression (>16% by lower quartile), 5-year
survival was 57% and the 10-year survival was 47%. In the
group with low Ki-67 positivity, the 5- and 10 year sur-
vival were 89% and 86%, respectively. In contrast, the sur-
vival analyses did not show any significant influence of
Figure 2 Scatter plots with regression lines illustrating the relationships between mitotic count (mitosis/mm2), Ki-67 expression and PHH3 
expression.
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Page 8 of 15PHH3, MCM4, mitosin or Cdc6 on outcome (Fig. 3;
Table 3).
In the multivariate analysis (proportional hazards
method), we first examined the histopathological vari-
ables included in the pT system from 2010, tumor thick-
ness, tumor ulceration, and mitotic count. In this basic
model, tumor thickness >4.0 mm was a predictor of poor
prognosis compared with tumors ≤2.0 mm (HR = 2.4, p =
0.020). Presence of ulceration (HR = 1.7; p = 0.028) was
also a prognostic indicator in this model, whereas mitotic
count was not, even if it was included as a continuous
variable, or if other cut-points were used. Next, the same
variables were included together with Ki-67 expression in
a new model (Table 4). Tumor thickness >4.0 mm com-
pared with ≤2.0 mm (p = 0.041) and level of Ki-67 expres-
sion (p = 0.003) were significant predictors of prognosis
in this model, whereas ulceration and mitotic count were
not. Further, we also included other histopathological
variables that were previously shown to be strong prog-
nostic indicators in this series by univariate analysis, i.e.
Clark's level of invasion, vascular infiltration and tumor
necrosis (Table 5). In this model, Clark's level (p = 0.009),
vascular invasion (p = 0.008), tumor necrosis (p = 0.015),
and Ki-67 expression (p = 0.006) showed prognostic
impact, whereas tumor thickness, ulceration, and mitotic
count did not. Exclusion of Ki-67 did not influence the
impact of mitotic count in the model.
If tumor thickness was included as a continuous vari-
able, thickness was a significant prognostic indicator, also
in the model shown in Table 5. Additional analyses
showed that this was due to a small subgroup (n = 13) of
tumors >10 mm with very poor prognosis. However, the
prognostic impact of mitotic count and Ki-67 were not
altered if thickness was used as a continuous variable.
In this series of nodular melanomas, location on the
trunk compared with other locations had significant
prognostic impact in univariate (p < 0.001) and multivari-
ate analyses (HR = 2.6, p = 0.002, if added to the model
shown in Table 5), but it did not influence the impact of
mitotic count or Ki-67 expression. Age and sex were not
correlated with survival in univariate analyses, and did
not alter the multivariate survival analyses if included.
Discussion
Increased tumor cell proliferation is a hallmark of malig-
nancy [40] and also a prognostic factor in multiple
tumors, among these cutaneous melanoma. Assessment
of proliferation may facilitate more accurate staging of
melanomas, and thereby be an aid in the selection of
patients for treatment.
In the present study of thick cutaneous melanomas,
increased mitotic count and Ki-67 expression were both
associated with known unfavourable features, such as
increased tumor thickness, Clark's levels of invasion,
presence of tumor ulceration, tumor necrosis and vascu-
lar invasion. High mitotic count was a predictor of poor
prognosis in univariate analysis, while increased percent-
Table 2: Mitotic count and Ki-67 in association with expression of PHH3, MCM4 and mitosin
Mitotic count Ki-67
(no./mm2) (% pos)
median p-valuea median p-valuea
PHH3 (% pos) 0.003 0.002
≤0.8b 3.4 26.0
>0.8 8.9 36.0
MCM4 (% pos) 0.002 0.001
≤40.7b 5.1 26.0
>40.7 11.1 37.5
Mitosin (SId) ns ns
lowc 9.4 34.5
high 7.7 31.5
aMann-Whitney test
bCut-off point median
cCut-off point lower quartile
dAbbreviation: SI, staining index
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Table 3: Univariate survival analysis according to histopathological variables and proliferation markers
Variables n Estimated survival rates (%) p-valuea
5 years 10 years
Tumor thickness 0.001
≤2.0 mm 48 80 77
2.1-4.0 mm 73 76 59
>4.0 mm 81 49 43
Tumor ulceration 0.001
absent 114 77 68
present 83 54 44
Clark's level <0.001
II - IV 166 72 62
V 35 40 32
Vascular infiltration <0.001
absent 162 73 61
present 40 39 39
Tumor necrosis <0.001
absent 142 76 64
present 57 39 36
Mitotic count (no./
mm2)
0.008
<1.7b 35 84 84
≥1.7 164 62 51
Ki-67 (% pos) <0.0001
≤16b 49 89 86
>16 138 57 47
PHH3 (% pos) ns
≤0.8c 56 67 47
>0.8 55 57 50
MCM4 (% pos) ns
≤40.7c 48 61 43
>40.7 48 58 46
Mitosin (SId) ns
lowb 45 58 47
high 58 59 42
aLog-rank test
bCut-off point lower quartile
cCut-off point median
dAbbreviation: SI, staining index
Ladstein et al. BMC Cancer 2010, 10:140
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Figure 3 Survival curves according to the Kaplan-Meier method with cut-off points at the lower quartile for mitotic count (<1.7 mitotic fig-
ures/mm2), Ki-67 expression (≤16% positive tumor cell nuclei) and mitosin (SI ≤ 6), and at the median values for PHH3 (≤0.8% positive nu-
clei) and MCM4 (≤40.7% positive nuclei).
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Page 11 of 15age of Ki-67 positivity in tumor cells was stronger in mul-
tivariate survival models.
Mitotic count has shown an independent prognostic
value in several studies of primary melanoma [6,7,10],
whereas others have shown prognostic significance of
mitotic count in univariate analysis only [8,41], as in the
present study. Some authors claim that mitotic count
should not be incorporated in the routine staging system
due to limited additional prognostic information [41].
The reproducebility and the time consume are also
important aspects to consider [41]. Nevertheless, the
majority of authors seem to be of the opinion that assess-
ment of mitoses should be incorporated in the staging of
cutaneous melanoma [6-11]. Therefore, in the latest
AJCC classification system from 2010, mitotic count has
been included in the substaging of pT1 tumors.
Ki-67 has been the most widely used proliferation
marker in melanomas and other tumors. In a recent
review, Ki-67 staining was considered a helpful supple-
ment in distinguishing benign from malignant melano-
cytic lesions, but the prognostic value is more uncertain
in melanomas [12]. Still, in a systematic review and meta-
analysis of published literature on prognostic immuno-
histochemical biomarkers in cutaneous melanoma, Ki-67
was among the most promising [42]. This analysis
included the previously published data from the present
study [13]. A limitation in the use of Ki-67 is the lack of
methodological standardization and a validated cut-off
level. This is a possible bias in comparing different stud-
ies, and restricts the utility in a routine setting. Thus,
alternative methods of proliferation assessment are of
interest, in particular if they could be used in routine
practice. Since only a subset of the cells expressing Ki-67
in fact will go through mitosis [43], one important aim of
this study was to investigate whether mitotic count was a
better way to estimate proliferation and prognosis, and to
compare the impact of Ki-67 with mitotic count and a
selection of more recently introduced proliferation mark-
ers.
To the best of our knowledge, there are few previous
studies on cutaneous melanomas with data on both
mitotic count and Ki-67 expression included in multivari-
ate prognostic analyses, and no such studies on thick mel-
anomas. A cohort study by Gimotty et al. on 396 thin
melanomas (tumor thickness ≤1 mm) with at least 10
years follow-up, showed mitotic count ≥1 per mm2 and
Ki-67 expression in ≥20% of tumor cell nuclei to be inde-
pendent prognostic factors of metastases [9]. Presence of
mitoses had the strongest prognostic impact. In another
study of 169 thin melanomas, Frahm et al. found 5 cases
with high Ki-67 expression (≥25% positive tumor cells) of
which 4 developed metastases, and in the multivariate
Table 4: Multivariate survival analysis (Cox' proportional hazards method)
Variable n HRa 95% CI p-valueb
Tumor thickness 0.073
≤2.0 mm 43 1
2.1-4.0 mm 65 1.7 0.7 to 4.1 ns
>4.0 mm 72 2.5 1.04 to 5.8 0.041
Tumor ulceration 0.083
absent 102 1
present 78 1.6 0.9 to 2.6
Mitotic count 
(no./mm2)
ns
<1.7c 34 1
≥1.7 146 1.5 0.6 to 3.9
Ki-67 (% pos) 0.003
≤16c 48 1
>16 132 3.1 1.3 to 7.4
aHazard ratio
bLikelihood ratio or Wald test
cCut-off point lower quartile
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Page 12 of 15analyses, no other factors, included mitotic count, turned
out to be independently predictive [44].
Mitosis can be difficult to distinguish from apoptotic
figures. In this respect, the mitotic marker anti-PHH3 is
interesting, as it lightens up mitosis that appear as sharply
stained figures, whereas apoptotic cells remain negative
[19,45]. Especially, prophases are emphasized, in line with
previous reports [45]. In the present study, PHH3 was
associated with tumor thickness, ulceration and necrosis
in the group of nodular melanomas. Since PHH3 corre-
lated significantly with mitotic count and Ki-67 expres-
sion, it was surprising that the PHH3 frequency did not
show an association with patient outcome. An obvious
objection and possible weakness in the method was that
mitotic count and Ki-67 was assessed on whole sections,
while PHH3 staining was performed on TMA sections.
However, there was a good correlation between the
PHH3 frequency in TMA and standard sections.
The median number of PHH3 positive cells per mm2
was higher than the median value of the mitotic count per
mm2 in the regular slides (ratio 2.4). This is expected, as
fewer mitotic figures should be missed when they are
Table 5: Multivariate survival analysis (Cox' proportional hazards method)
Variable n HRa 95% CI p-valueb
Tumor thickness ns
≤2.0 mm 43 1
2.1-4.0 mm 64 1.3 0.5 to 3.2 ns
>4.0 mm 72 1.1 0.4 to 2.9 ns
Tumor ulceration ns
absent 101 1
present 78 1.3 0.7 to 2.3
Clark's level 0.009
II - IV 146 1
V 33 2.5 1.3 to 4.9
Vascular 
infiltration
0.008
absent 143 1
present 36 2.3 1.3 to 4.0
Tumor necrosis 0.015
absent 127 1
present 52 2.1 1.2 to 3.8
Mitotic count 
(no./mm2)
ns
<1.7c 34 1
≥1.7 145 1.5 0.5 to 3.9
Ki-67 (% pos) 0.006
≤16c 48 1
>16 131 3.0 1.3 to 7.3
aHazard ratio
bLikelihood ratio or Wald test
cCut-off point lower quartile
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Page 13 of 15highlighted by staining, and prophases are impossible to
count on standard HE-sections. Corresponding results
with increased number of identified mitosis by using
PHH3 staining are described in other tumor types such as
breast cancer [17,19,45,46]. Based on these findings,
PHH3 frequency does not appear to be a useful prolifera-
tion marker in cutaneous melanoma, although we believe
that this should be studied in more detail.
MCM4 was associated with mitotic count and Ki-67
expression, but there was no influence on survival related
to the level of MCM4 expression. In the metastases,
MCM4 staining was actually lower than in primary
tumors. Thus, these findings did not validate MCM4 as a
prognostic marker in cutaneous melanoma as reported
by Winnepenninckx [21].
Mitosin did not turn out as a useful proliferation
marker in the present study, as it was not correlated to
any of the investigated variables, including Ki-67 and
mitotic count, nor to patient survival. Further, our results
did not confirm an increased expression in metastases as
compared with primary melanomas as described in a
gene expression study of non-paired primary tumors and
metastases [24]. In contrast, we found that expression of
mitosin was lower in the metastases. In a study of breast
cancer which showed a prognostic value of mitosin [26],
the same CENPF antibody in equivalent dilution was
used.
The present study did not show an inverse association
between expression of Cdc6 and the p16 tumor suppres-
sor protein. Further, Cdc6 was not a useful proliferation
marker, despite being correlated with PHH3, with no pre-
diction of survival. Jaeger et al. identified Cdc6 among
upregulated genes in melanoma metastases compared to
primary tumors as validated by immunohistochemistry
[24]. Cdc6 was also in the group of genes associated with
an unfavourable prognosis in a different gene expression
study by Winnepenninckx et al [21]. However, in a subse-
quent immunohistochemical staining on TMA, Cdc6 was
not a significant prognostic predictor, in line with our
findings.
Strong EZH2 expression was associated with increased
Ki-67 staining and mitotic counts as previously reported
[32]. Also, high levels of PHH3 and elevated MCM4
expression were significantly correlated with strong
EZH2. Association between proliferation by Ki-67 and
expression of EZH2 has been shown in several other
tumors such as prostate [32], breast [47], salivary gland
adenoid cystic carcinoma [48], and oral squamous cell
carcinoma [49]. EZH2 promotes S-phase entry and G2-
M transition [50,51], and the epigenetic modifying effects
of EZH2 histone methyltransferase is involved in silenc-
ing of cell cycle control genes [52].
Conclusions
In conclusion, Ki-67 was a stronger and more robust
prognostic indicator than mitotic count in this series of
nodular melanomas (median thickness 3.6 mm).
Although the novel proliferation markers PHH3 and
MCM4 were significantly correlated with Ki-67 and
mitotic counts, they did not predict patient survival.
Therefore, Ki-67 expression was a superior proliferation
marker in this series of thick cutaneous melanoma
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